Neogenomics

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board, with revenue of $201.7M (+11% YoY) surpassing the $197.0M expected. The beat was driven by a 14% increase in clinical services, particularly 26% growth in Next-Generation Sequencing (NGS). GAAP Net Income of $2.2M significantly outperformed the expected loss of $16.5M, aided by an $11M debt extinguishment gain. Strong performance led management to raise FY26 revenue guidance to $802M-$806M and Adjusted EBITDA to $56M-$58M.